

DAFTAR PUSTAKA

- [1] World Health Organization, "Cancer." <https://www.who.int/news-room/fact-sheets/detail/cancer> (diakses Jan 24, 2023).
- [2] World Health Organization, "Cancer Indonesia 2020 country profile." <https://www.who.int/publications/m/item/cancer-idn-2020> (diakses Jan 24, 2023).
- [3] S. Pangribowo, "BEBAN KANKER DI INDONESIA," Jakarta, 2019.
- [4] Z. Abbas dan S. Rehman, "An Overview of Cancer Treatment Modalities," dalam *Neoplasm*, InTech, 2018. doi: 10.5772/intechopen.76558.
- [5] X. Tian, K. Liu, Y. Hou, J. Cheng, dan J. Zhang, "The evolution of proton beam therapy: Current and future status (Review)," *Mol Clin Oncol*, Nov 2017, doi: 10.3892/mco.2017.1499.
- [6] H. Harada dan S. Murayama, "Proton beam therapy in non-small cell lung cancer: State of the art," *Lung Cancer: Targets and Therapy*, vol. 8. Dove Medical Press Ltd., hlm. 141–145, Agu 23, 2017. doi: 10.2147/LCTT.S117647.
- [7] M. Chuong *dkk.*, "Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer," *J Gastrointest Oncol*, vol. 9, no. 4, hlm. 687–693, Agu 2018, doi: 10.21037/jgo.2018.03.14.
- [8] M-Cristy, "ORNL/TM-9487 Dist. Category UC-41 Health and Safety Research Division MATHEMATICAL PHANTOMS FOR USE IN REASSESSMENT OF RADIATION DOSES TO JAPANESE ATOMIC-BOMB SURVIVORS."
- [9] International Commission on Radiological Protection. dan International Commission on Radiation Units and Measurements., *Adult reference computational phantoms : joint ICRP/ICRU report*. Polestar Wheatons Ltd, 2009.
- [10] R. Pidikiti *dkk.*, "Commissioning of the world's first compact pencil-beam scanning proton therapy system," *J Appl Clin Med Phys*, vol. 19, no. 1, hlm. 94–105, Jan 2018, doi: 10.1002/acm2.12225.
- [11] U. Bayasgalan, S. H. Moon, T. H. Kim, T. Y. Kim, S. H. Lee, dan Y. G. Suh, "Dosimetric comparisons between proton beam therapy and modern photon radiation techniques for stage I non-small cell lung cancer according to tumor location," *Cancers (Basel)*, vol. 13, no. 24, Des 2021, doi: 10.3390/cancers13246356.

- [12] M. Hata *dkk.*, “Hypofractionated High-Dose Proton Beam Therapy for Stage I Non-Small-Cell Lung Cancer: Preliminary Results of A Phase I/II Clinical Study,” *Int J Radiat Oncol Biol Phys*, vol. 68, no. 3, hlm. 786–793, Jul 2007, doi: 10.1016/j.ijrobp.2006.12.063.
- [13] D. A. Bush, J. D. Slater, B. B. Shin, G. Cheek, D. W. Miller, dan J. M. Slater, “Hypofractionated proton beam radiotherapy for stage I lung cancer,” *Chest*, vol. 126, no. 4, hlm. 1198–1203, 2004, doi: 10.1378/chest.126.4.1198.
- [14] S. U. Lee *dkk.*, “Ablativ dosierte Protonentherapie bei Stadium-I- und rekurrenden nichtkleinzelligen Lungenkarzinomen: Ablativ dosierte Protonentherapie für NSCLC,” *Strahlentherapie und Onkologie*, vol. 192, no. 9, hlm. 649–657, Sep 2016, doi: 10.1007/s00066-016-0985-9.
- [15] A. Patwa dan A. Shah, “Anatomy and physiology of respiratory system relevant to anaesthesia,” *Indian Journal of Anaesthesia*, vol. 59, no. 9. Indian Society of Anaesthetists, hlm. 533–541, Sep 01, 2015. doi: 10.4103/0019-5049.165849.
- [16] R. Chaudhry dan B. Bordoni, “Anatomy, Thorax, Lungs,” *StatPearls*, Jul 2022, Diakses: Jan 24, 2023. [Daring]. Available: <https://www.ncbi.nlm.nih.gov/books/NBK470197/>
- [17] “Lung | Definition, Function, & Facts | Britannica.” <https://www.britannica.com/science/lung> (diakses Jan 24, 2023).
- [18] “Lung Cancer: Types, Stages, Symptoms, Diagnosis & Treatment.” <https://my.clevelandclinic.org/health/diseases/4375-lung-cancer> (diakses Jan 24, 2023).
- [19] “What Is Lung Cancer? | Types of Lung Cancer.” <https://www.cancer.org/cancer/lung-cancer/about/what-is.html> (diakses Jan 24, 2023).
- [20] O. Lababede dan M. A. Meziane, “The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams Downloaded from,” *Brief Communications Published Ahead of Print on April*, vol. 23, hlm. 1–5, 2018, doi: 10.1634/theoncology.
- [21] W. D. Newhauser dan R. Zhang, “The physics of proton therapy,” *Physics in Medicine and Biology*, vol. 60, no. 8. Institute of Physics Publishing, hlm. R155–R209, Apr 21, 2015. doi: 10.1088/0031-9155/60/8/R155.
- [22] L. Grevillot, “Monte Carlo simulation of active scanning proton therapy system with Gate/Geant4 : Towards a better patient dose quality assurance,” 2011. [Daring]. Available: <http://theses.insa-lyon.fr/publication/2011ISAL0101/these.pdf>

- [23] “Proton Therapy: Behind the Scenes,” 2023. [Daring]. Available: www.oncolink.org
- [24] M. A. L. Vyfhuis *dkk.*, “Advances in proton therapy in lung cancer,” *Therapeutic Advances in Respiratory Disease*, vol. 12. SAGE Publications Ltd, Jul 14, 2018. doi: 10.1177/1753466618783878.
- [25] S. Fukumoto, “CYCLOTRON VERSUS SYNCHROTRON FOR PROTON BEAM THERAPY.”
- [26] H. K. Byun *dkk.*, “Physical and Biological Characteristics of Particle Therapy for Oncologists,” *Cancer Res Treat*, vol. 53, no. 3, hlm. 611–620, Jul 2021, doi: 10.4143/crt.2021.066.
- [27] D. Jette dan W. Chen, “Creating a spread-out Bragg peak in proton beams,” *Phys Med Biol*, vol. 56, no. 11, Jun 2011, doi: 10.1088/0031-9155/56/11/N01.
- [28] T. Sato *dkk.*, “Overview of the PHITS code and its application to medical physics,” *Progress in Nuclear Science and Technology*, vol. 4, hlm. 879–882, 2014, doi: 10.15669/pnst.4.879.
- [29] K. Niita, T. Sato, H. Iwase, H. Nose, H. Nakashima, dan L. Sihver, “PHITS-a particle and heavy ion transport code system,” *Radiat Meas*, vol. 41, no. 9–10, hlm. 1080–1090, Okt 2006, doi: 10.1016/j.radmeas.2006.07.013.
- [30] T. Sato, S. Iwamoto, T. Hashimoto, Furuta T., dan Abe S., “PHITS 3.28 User Manual,” 2022.
- [31] J. W. Leer, “What the clinician wants to know: radiation oncology perspective,” *Cancer Imaging*, vol. 5 Spec No A, 2005, doi: 10.1102/1470-7330.2005.0027.
- [32] N. G. Burnet, S. J. Thomas, K. E. Burton, dan S. J. Jefferies, “Defining the tumour and target volumes for radiotherapy,” *Cancer Imaging*, vol. 4, no. 2, hlm. 153–161, 2004, doi: 10.1102/1470-7330.2004.0054.
- [33] “Dosimetry Aspects of Proton Therapy”, [Daring]. Available: www.tcrt.org
- [34] I. Nagata, T. Ogino, T. Arimura, dan T. Yoshiura, “Clinical outcomes of proton beam therapy for ground-glass opacity-type lung cancer,” *Lung Cancer: Targets and Therapy*, vol. 11, hlm. 105–111, 2020, doi: 10.2147/LCTT.S270283.
- [35] “English Translation of JASTRO treatment policy of proton beam therapy. Ver 1.0 at 2016 May (https://www.jastro.or.jp/particle_beam/detail.php?eid=00002) This treatment policy can be changed at any time without notice. Disease

Radiotherapy.” [Daring]. Available:
https://www.jastro.or.jp/particle_beam/detail.php?eid=00002

- [36] G. Mitchell, “The rationale for fractionation in radiotherapy,” *Clin J Oncol Nurs*, vol. 17, no. 4, hlm. 412–417, 2013, doi: 10.1188/13.CJON.412-417.
- [37] M. Lambrecht *dkk.*, “Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus,” *Radiotherapy and Oncology*, vol. 128, no. 1. Elsevier Ireland Ltd, hlm. 26–36, Jul 01, 2018. doi: 10.1016/j.radonc.2018.05.001.
- [38] S. Bisello *dkk.*, “Dose–Volume Constraints fOr oRganS At risk In Radiotherapy (CORSAIR): An ‘All-in-One’ Multicenter–Multidisciplinary Practical Summary,” *Current Oncology*, vol. 29, no. 10. MDPI, hlm. 7021–7050, Okt 01, 2022. doi: 10.3390/curroncol29100552.
- [39] J. Grimm, T. LaCouture, R. Croce, I. Yeo, Y. Zhu, dan J. Xue, “Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy,” *J Appl Clin Med Phys*, vol. 12, no. 2, hlm. 267–292, 2011, doi: 10.1120/jacmp.v12i2.3368.